NASDAQ: SHPHShuttle Pharmaceuticals Holdings Inc Stock
$3.13-0.40 (-11.33%)
Updated Sep 16, 2026
SHPH Price
$3.13
Fair Value Price
$0.62
Market Cap
$1.83M
52 Week Low
$2.58
52 Week High
$55.90
P/E
-0.07x
P/B
0.55x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$10.82M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.53
Operating Cash Flow
-$9M
Beta
0.54
Next Earnings
Sep 22, 2026
Ex-Dividend
N/A
Next Dividend
N/A
SHPH Overview
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SHPH's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
SHPH
Ranked#51 of 54
Ranked#51 of 54
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $5.69 | A | |
| $56.35 | A | |
| $34.35 | A |
Be the first to know about important SHPH news, forecast changes, insider trades & much more!
SHPH News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SHPH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SHPH ($3.13) is overvalued by 403.32% relative to our estimate of its Fair Value price of $0.62 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SHPH ($3.13) is not significantly undervalued (403.32%) relative to our estimate of its Fair Value price of $0.62 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SHPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SHPH due diligence checks available for Premium users.
Valuation
SHPH fair value
Fair Value of SHPH stock based on Discounted Cash Flow (DCF)
Price
$3.13
Fair Value
$0.62
Overvalued by
403.32%
SHPH ($3.13) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SHPH ($3.13) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SHPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SHPH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.07x
Industry
2.57x
Market
44.18x
SHPH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.55x
Industry
2.35x
SHPH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SHPH's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.2M
Profit Margin
0%
SHPH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$11.8M
Liabilities
$8.5M
Debt to equity
2.53
SHPH's short-term liabilities ($8.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SHPH's short-term assets ($2.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SHPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.4M
Investing
-$36.0k
Financing
$3.2M
SHPH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SHPH vs Pharmaceutical Stocks
Shuttle Pharmaceuticals Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.